Nov 14, 2025 7:00 am EST TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Nov 3, 2025 9:01 am EST TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
Aug 20, 2025 8:00 am EDT TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
Aug 14, 2025 4:15 pm EDT TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Jul 1, 2025 8:50 am EDT TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Jun 24, 2025 8:00 am EDT TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
Jun 23, 2025 5:00 pm EDT TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
Jun 9, 2025 8:00 am EDT FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
Jun 3, 2025 9:58 am EDT TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy